Trade SARTORIUS AG O.N. - SRT CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 1.5
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment€1,000.00Overnight funding adjustmentCharges from full value of position-0.01802 %(-€3.60)Trade size with leverage ~ €20,000.00Money from leverage ~ $€19,000.00Go to platform: -0.01802%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment€1,000.00Overnight funding adjustmentCharges from full value of position-0.00420 %(-€0.84)Trade size with leverage ~ €20,000.00Money from leverage ~ $€19,000.00Go to platform: -0.00420%
• Overnight funding adjustment time: 22:00 (UTC)
• Currency: EUR
• Min traded quantity: 0.1
• Margin: 5.00%
• Stock exchange: Germany
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: €1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.01802 %
  (-€3.60)

• Margin. Your investment: €1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.00420 %
  (-€0.84)

Key Stats

• Prev. Close: 229.25
• Open: 229.75
• 1-Year Change: 31.59%
• Day's Range: 222.25 - 230.75

Trade SARTORIUS AG O.N. - SRT

About Sartorius AG

Sartorius AG is a Germany-based supplier of pharmaceutical and laboratory equipment. It operates through two segments: Bioprocess Solutions and Lab Products and Services. The Bioprocess Solutions segment offers integrated solutions for biopharmaceutical manufacture, such as filters for sterilization of biopharmaceutical media, single-use bags for cell cultivation and storage of biopharmaceuticals, membrane adsorbers for purification in bioprocesses, and filter technology for clarification, among others. The Lab Products and Services segment provides instruments, consumables and services for laboratories, including laboratory balances, laboratory water systems for storage of purified water, electronic pipettes, filter systems for sample preparation and membrane filter systems for sterility testing of parenterals.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Sartorius AG revenues increased 48% to EUR3.45B. Net income increased 52% to EUR318.9M. Revenues reflect Bioprocess Solutions segment increase of 53% to EUR2.73B, Lab Products and Services segment increase of 31% to EUR722.2M, Europe (Region)-Germany (Country)-France (Country) segment increase of 53% to EUR1.05B, United States (Country) segment increase of 41% to EUR1.06B.

Equity composition

6/2016, Scrip Issue, 3 new share for every 1 share held (Factor: 4).